The speed of vaccination, plasma collection, and antibody purification (3–5 months) and the relatively low costs (compared to monoclonal antibody development) make TcB-derived polyclonal antibodies a promising choice for emerging or rare infectious diseases. The gene discussed is PKM; the disease is infectious disease.